Robert John Mentz

Robert John Mentz's AcademicInfluence.com Rankings

Robert John Mentz

Philosophy

#8222

World Rank

#11559

Historical Rank

Logic

#5256

World Rank

#6641

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert John Mentz's Degrees

Bachelors Biology University of California, Berkeley
Doctorate Medicine University of California, San Francisco
Masters Clinical Research Duke University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Robert John Mentz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert John Mentz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (2017) (1265)
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. (2014) (422)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. (2017) (415)
Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. (2017) (369)
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. (2015) (285)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. (2019) (236)
Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality (2019) (202)
The continuous heart failure spectrum: moving beyond an ejection fraction classification. (2019) (170)
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. (2012) (163)
Association between diabetes mellitus and post‐discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial (2013) (162)
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. (2019) (162)
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial (2017) (161)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (2022) (160)
Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. (2017) (158)
Diuretics and ultrafiltration in acute decompensated heart failure. (2012) (153)
Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. (2021) (150)
Heart failure in elderly patients: distinctive features and unresolved issues (2013) (146)
Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). (2015) (144)
Haemoconcentration, renal function, and post‐discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial (2013) (124)
The PROTECT in‐hospital risk model: 7‐day outcome in patients hospitalized with acute heart failure and renal dysfunction (2012) (118)
Decongestion in acute heart failure (2014) (115)
Patient selection in heart failure with preserved ejection fraction clinical trials. (2015) (114)
Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX‐AHF study (2015) (111)
The past, present and future of renin-angiotensin aldosterone system inhibition. (2013) (106)
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. (2015) (105)
Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights from DOSE-AHF and CARRESS-HF (2015) (104)
Pathophysiology and clinical evaluation of acute heart failure (2016) (104)
Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow? (2016) (101)
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). (2017) (99)
Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE‐HF (2012) (99)
Charting a roadmap for heart failure biomarker studies. (2014) (95)
Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction: Insights From the REHAB-HF Trial (2018) (93)
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. (2013) (86)
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. (2016) (85)
Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. (2017) (82)
Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). (2013) (81)
Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights from the EVEREST Trial (2012) (78)
Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials. (2016) (76)
10-Year Risk Equations for Incident Heart Failure in the General Population. (2019) (76)
International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short‐term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial (2014) (74)
Reassessing Recipient Mortality Under the New Heart Allocation System: An Updated UNOS Registry Analysis. (2020) (74)
Outpatient Worsening Heart Failure as a Target for Therapy: A Review (2018) (73)
d-Dimer elevation and adverse outcomes (2014) (72)
Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study (2018) (72)
Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). (2013) (71)
A reappraisal of loop diuretic choice in heart failure patients. (2015) (71)
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. (2012) (67)
Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds. (2016) (66)
Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. (2017) (63)
Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement (2018) (63)
Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB‐HF) trial: Design and rationale (2017) (63)
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. (2017) (62)
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. (2013) (61)
Home-Time After Discharge Among Patients Hospitalized With Heart Failure. (2018) (57)
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). (2014) (57)
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions (2014) (56)
Regional adiposity and heart failure with preserved ejection fraction (2020) (54)
In‐Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization (2014) (54)
Frailty Among Older Decompensated Heart Failure Patients: Prevalence, Association With Patient-Centered Outcomes, and Efficient Detection Methods. (2019) (54)
Noncardiac comorbidities and acute heart failure patients. (2013) (52)
Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. (2017) (52)
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2013) (49)
Predictors of early dyspnoea relief in acute heart failure and the association with 30‐day outcomes: findings from ASCEND‐HF (2013) (48)
The palliative care in heart failure trial: rationale and design. (2014) (48)
Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes (2014) (46)
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (2017) (46)
Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) (2018) (46)
Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. (2016) (45)
Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND‐HF (2018) (44)
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. (2019) (44)
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial (2019) (44)
Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. (2017) (44)
Implications of geographical variation on clinical outcomes of cardiovascular trials. (2012) (44)
Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. (2019) (43)
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial (2015) (43)
Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). (2015) (43)
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. (2021) (43)
Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? (2017) (42)
Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure. (2020) (42)
Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND‐HF (2016) (41)
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). (2016) (41)
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. (2014) (38)
Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). (2015) (38)
Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. (2015) (37)
Comorbidities in Heart Failure: Are There Gender Differences? (2016) (37)
Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. (2019) (36)
The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions (2018) (36)
Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial (2018) (36)
Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study (2017) (36)
Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. (2016) (36)
Population-Attributable Risk for Cardiovascular Disease Associated With Hypertension in Black Adults. (2019) (36)
Characteristics and Trends Among Patients With Cardiovascular Disease Referred to Palliative Care (2019) (35)
Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Findings From the EVEREST Trial (2014) (35)
Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. (2016) (35)
The burden of proof: The current state of atrial fibrillation prevention and treatment trials. (2017) (34)
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial (2019) (34)
Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET‐HF‐DM Trial (2019) (34)
Clinical profiles in acute heart failure: an urgent need for a new approach (2019) (34)
Learning from recent trials and shaping the future of acute heart failure trials. (2013) (34)
Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure (2020) (34)
Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study (2019) (33)
The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND‐HF (2016) (33)
Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. (2016) (33)
Relationship between changing patient‐reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF‐ACTION (2018) (32)
Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. (2019) (32)
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? (2017) (32)
Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. (2018) (32)
Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). (2014) (32)
Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? (2012) (31)
Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. (2019) (31)
Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support (2017) (31)
Perceived Discrimination and Cardiovascular Outcomes in Older African Americans: Insights From the Jackson Heart Study (2017) (31)
Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes (2017) (30)
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL (2019) (30)
Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF‐ACTION)trial (2017) (30)
Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease). (2012) (29)
Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From ASCEND-HF. (2016) (29)
Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. (2015) (29)
Low risk pragmatic trials do not always require participants’ informed consent (2019) (29)
Atherosclerosis: Recent trials, new targets and future directions. (2015) (29)
Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. (2015) (28)
Conduct of Clinical Trials in the Era of COVID-19 (2020) (28)
Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). (2016) (28)
Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION). (2013) (28)
Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study (2017) (28)
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry (2020) (28)
Acute Heart Failure: Alternatives to Hospitalization. (2017) (28)
Increasing the United States heart transplant donor pool with donation after circulatory death. (2020) (28)
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL (2018) (27)
Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure: The HF-ACTION Trial. (2018) (27)
Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. (2021) (26)
Epidemiology of cardiorenal syndrome. (2010) (26)
Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. (2019) (26)
Heart failure event definitions in drug trials in patients with type 2 diabetes. (2016) (25)
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). (2016) (25)
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial (2022) (25)
Multinational and multiethnic variations in health‐related quality of life in patients with chronic heart failure (2017) (25)
Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial (2015) (25)
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. (2018) (24)
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. (2021) (24)
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. (2015) (24)
Torsemide Versus Furosemide in Heart Failure Patients: Insights From Duke University Hospital (2015) (24)
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. (2012) (24)
Medical Management of Patients With Continuous-Flow Left Ventricular Assist Devices (2014) (24)
Sleep Breathing Disorders in Heart Failure. (2020) (24)
Multi‐ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF‐ACTION trial and the ASIAN‐HF registry (2018) (24)
Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. (2016) (23)
High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network (2018) (23)
Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study (2017) (23)
Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. (2016) (23)
Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction (2021) (23)
Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. (2021) (23)
Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks: The Jackson Heart Study (2018) (23)
Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction (2016) (23)
Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the ASCEND‐HF trial (2017) (23)
Sleep-disordered breathing in patients with heart failure. (2014) (22)
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF (2018) (22)
Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. (2016) (22)
Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index (2020) (22)
Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure PatientsCLINICAL PERSPECTIVE (2015) (22)
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial (2022) (22)
Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials (2015) (21)
Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction (2015) (21)
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. (2019) (21)
Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND‐HF (2018) (20)
Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. (2020) (20)
Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial. (2018) (20)
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial (2013) (20)
Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans: Insights From the Jackson Heart Study (2015) (20)
Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. (2019) (20)
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial (2016) (20)
Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data (2017) (19)
Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. (2021) (19)
Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. (2015) (19)
Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND‐HF (2015) (19)
The burden of non‐cardiac comorbidities and association with clinical outcomes in an acute heart failure trial – insights from ASCEND‐HF (2020) (19)
Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. (2019) (19)
Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. (2021) (19)
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. (2015) (19)
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial (2017) (19)
Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. (2019) (18)
Sex Differences in Heart Failure. (2021) (18)
Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. (2021) (18)
Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure (2018) (18)
Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study. (2017) (18)
The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. (2016) (17)
Cigarette Smoking and Subclinical Peripheral Arterial Disease in Blacks of the Jackson Heart Study (2019) (17)
Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure (2020) (17)
Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events (2014) (16)
Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure (2021) (16)
Site selection for heart failure clinical trials in the USA (2015) (16)
Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL‐HF trial (2016) (16)
Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis. (2020) (16)
Cognition, Physical Function and Quality-of-Life in Older Patients with Acute Decompensated Heart Failure. (2020) (16)
A crisis of the heart: an acute reversible cardiomyopathy bridged to recovery in a patient with Addison's disease. (2013) (16)
Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. (2015) (16)
Causes of hospitalization in the USA between 2005 and 2018 (2021) (15)
Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial (2018) (15)
Development and Validation of Machine Learning–Based Race-Specific Models to Predict 10-Year Risk of Heart Failure (2021) (15)
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial (2020) (15)
Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). (2018) (14)
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. (2021) (14)
Neural modulation for hypertension and heart failure. (2016) (14)
Trends in Place of Death for Individuals With Cardiovascular Disease in the United States. (2019) (14)
Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials (2016) (14)
STARBRIGHT World: A Pilot Study of a Home-Based Sickle Cell Psychoeducational Intervention (2006) (13)
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF (2022) (13)
Natriuretic Peptide-guided therapy for heart failure. (2011) (13)
Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). (2016) (13)
Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. (2021) (13)
Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials (2020) (13)
Longitudinal Strain in Heart Failure With Preserved Ejection Fraction: Is There a Role for Prognostication? (2015) (12)
End-of-life Heart Failure Care in the United States. (2015) (12)
A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response (2020) (12)
The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes (2018) (12)
Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart Study). (2018) (12)
Cardiorenal Interactions. (2016) (12)
Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). (2016) (12)
Acute heart failure in the young: Clinical characteristics and biomarker profiles. (2016) (11)
Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). (2017) (11)
PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. (2020) (11)
Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. (2019) (11)
Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. (2016) (11)
Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points: From the ASCEND-HF Trial (2018) (11)
Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) (2018) (11)
Drugs of Abuse and Heart Failure. (2021) (11)
Patient selection for advanced heart failure therapy referral. (2014) (11)
Intentional and unintentional medication non‐adherence in African Americans: Insights from the Jackson Heart Study (2018) (11)
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial (2020) (11)
Depressive symptoms, physical activity, and clinical events: The ADAPT prospective pilot study (2019) (10)
Management of newly treated diabetes in Medicare beneficiaries with and without heart failure (2017) (10)
Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). (2016) (10)
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (2019) (10)
African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial. (2019) (10)
Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. (2018) (10)
Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists (2015) (10)
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials (2022) (10)
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency (2021) (10)
Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study (2021) (10)
Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. (2018) (10)
Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019. (2022) (10)
Prognostic significance of depression in blacks with heart failure: insights from Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training. (2015) (9)
Site Principal Investigators in Multicenter Clinical Trials: Appropriately Recognizing Key Contributors. (2017) (9)
Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial (2019) (9)
Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). (2012) (9)
Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial (2022) (9)
Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). (2013) (9)
Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study (2021) (9)
Trends and outcomes of cardiac transplantation from donors dying of drug intoxication (2018) (9)
Assessment of Administrative Data to Identify Acute Myocardial Infarction in Electronic Health Records. (2016) (9)
Medical Therapy During Hospitalization for Heart Failure with Reduced Ejection Fraction: The VICTORIA Registry: Medical Therapy During Hospitalization for HFrEF. (2022) (9)
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin‐Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure (2019) (9)
Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction. (2019) (9)
Potential advantages of torsemide in patients with heart failure: more than just a ‘water pill’? (2018) (9)
Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. (2019) (9)
Effect of dimethyl sulfoxide on cooling rates of unrestrained rats. (1966) (8)
Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. (2020) (8)
The need for increased pragmatism in cardiovascular clinical trials (2022) (8)
Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices. (2019) (8)
Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. (2021) (8)
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change. (2022) (8)
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. (2021) (8)
Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study (2020) (8)
Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. (2022) (8)
Air Pollution in Patients With Heart Failure: Lessons From a Mechanistic Pilot Study of a Filter Intervention. (2016) (8)
Loop diuretic adjustments in patients with chronic heart failure: Insights from HF‐ACTION (2018) (8)
Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study. (2019) (8)
PROVIDE-HF primary results: Patient-reported outcomes inVestigation following initiation of drug therapy with Entresto (Sacubitril/valsartan) in heart failure. (2020) (8)
Prognostic Significance of Depression in African Americans With Heart Failure: Insights from HF-ACTION (2015) (8)
Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). (2014) (8)
Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. (2019) (7)
Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. (2021) (7)
Implications of Using Different Definitions on Outcomes in Worsening Heart Failure (2016) (7)
Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. (2015) (7)
Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials (2017) (7)
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes (2020) (7)
A call for collaboration: the evolving heart failure apprenticeship network. (2015) (7)
Abstract 10963: Comparable Benefit of Beta-Blocker Therapy in Heart Failure across Regions of the World: Meta-Analysis of Randomized Clinical Trials (2013) (7)
Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction (2017) (7)
Dysphagia in the setting of left ventricular assist device hemolysis. (2013) (6)
Hospice Care for Heart Failure: Challenges Faced by Hospice Staff in a Predominantly Rural Setting. (2019) (6)
Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF (2020) (6)
Death: The Simple Clinical Trial Endpoint (2019) (6)
Top Ten Tips for Palliative Care Clinicians Caring for Heart Failure Patients. (2018) (6)
Participation in a Heart Failure Clinical Trial (2021) (6)
Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction. (2021) (6)
Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. (2016) (6)
Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. (2020) (6)
Palliative Care in Heart Failure: Results of a Randomized, Controlled Clinical Trial (2016) (6)
Covariate adjustment in heart failure randomized controlled clinical trials: a case analysis of the HF-ACTION trial. (2011) (6)
Hyperkalemia in Heart Failure: Probably Not O“K” (2018) (6)
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). (2018) (6)
Donation after Circulatory Death in Heart Transplantation May Increase the Donor Pool by 20% in the U.S (2019) (6)
Contemplation from Our Hearts: A Call to Shift From Failure to Function. (2021) (6)
Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. (2020) (6)
Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure? (2013) (6)
Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. (2020) (6)
Spirituality in Patients With Heart Failure. (2022) (6)
The Placement of Aortic Transcatheter Valve (PARTNER) trial: a health economic and policy perspective. (2012) (6)
Suboptimal sleep and incident cardiovascular disease among African Americans in the Jackson Heart Study (JHS). (2020) (6)
Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF‐ACTION) randomized controlled trial (2018) (6)
Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End PointsCLINICAL PERSPECTIVE (2016) (6)
Physical Rehabilitation in Older Patients Hospitalized with Acute Heart Failure and Diabetes: Insights from REHAB-HF. (2021) (5)
Early impact of guideline publication on angiotensin‐receptor neprilysin inhibitor use among patients hospitalized for heart failure (2018) (5)
Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). (2017) (5)
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (2019) (5)
Relationship of physical function with quality of life in older patients with acute heart failure (2021) (5)
Epidemiology of cardiorenal syndrome. (2011) (5)
Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial. (2021) (5)
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. (2021) (5)
Paving a Better Path for Patients Dying of Heart Disease. (2018) (5)
Acute cardiovascular hospitalizations and illness severity before and during the COVID‐19 pandemic (2021) (5)
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial (2022) (5)
All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. (2019) (5)
Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure (2021) (5)
Cardiorenal syndrome clinical trial end points. (2011) (5)
Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction (2020) (5)
Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center. (2020) (5)
Balancing the Best of Both Worlds (2016) (4)
Renal Outcomes in Patients Bridged to Heart Transplant with a Left Ventricular Assist Device. (2020) (4)
Minimizing Seismocardiography Variability by Accounting for Respiratory Effects (2019) (4)
Potential SCG Predictors of Heart Failure Readmission (2020) (4)
Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. (2015) (4)
Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. (2020) (4)
Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial. (2023) (4)
Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial (2017) (4)
Machine Learning to Define Phenotypes and Outcomes of Patients Hospitalized for Heart Failure with Preserved Ejection Fraction: Findings from ASCEND-HF. (2022) (4)
Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial (2021) (4)
Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction. (2018) (4)
Hypertensive Diseases in Pregnancy and Kidney Function Later in Life: The Genetic Epidemiology Network of Arteriopathy (GENOA) Study. (2021) (4)
Association between body surface area and prescribed doses of guideline‐directed medications among international patients with heart failure and reduced ejection fraction (2019) (4)
Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study (2016) (4)
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel. (2022) (4)
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. (2023) (4)
Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research (2013) (4)
COPD in heart failure: are there long-term implications following acute heart failure hospitalization? (2015) (4)
Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. (2021) (4)
Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes (2018) (4)
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum (2022) (4)
Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event (2021) (4)
Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. (2015) (4)
Language Matters: Understanding Barriers to Medication Adherence to Better Tailor Heart Failure Care. (2021) (4)
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. (2021) (4)
Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries (2017) (3)
Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. (2020) (3)
Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillance (2021) (3)
Monday, 27 August 2012 (2012) (3)
THE ROLE OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICDS) IN PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE (LVAD): A SYSTEMATIC REVIEW AND META-ANALYSIS (2016) (3)
Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together. (2021) (3)
Out-Of-Pocket Payments for Part D Covered Medications by Medicare Fee-For-Service Beneficiaries with Heart Failure with Reduced Ejection Fraction. (2021) (3)
Plasma Volume Status and its Association with In-Hospital and Post-Discharge Outcomes in Decompensated Heart Failure. (2020) (3)
Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure (2021) (3)
A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF) (2020) (3)
Thoughtful selection and use of scientific terms in clinical research: the case of ‘pragmatic’ trials (2021) (3)
Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis (2020) (3)
Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women (2022) (3)
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. (2019) (3)
The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. (2021) (3)
Diversity, Equity and Inclusion at the Journal of Cardiac Failure. (2021) (3)
Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions (2020) (3)
Cardiac contractility modulation: the next cardiac resynchronization therapy or another renal sympathetic denervation? (2015) (3)
PHYSICAL FUNCTION, QUALITY OF LIFE, AND DEPRESSION IN ELDERLY, HOSPITALIZED PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE WITH PRESERVED VERSUS REDUCED EJECTION FRACTION: ANALYSIS FROM THE REHAB-HF TRIAL (2018) (3)
Early Diuretic Strategies and the Association With In-Hospital and Post-Discharge Outcomes in Acute Heart Failure. (2021) (3)
Abstract 252: PredischaRge Initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial (2019) (3)
Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation: Insights From the American Heart Association Get With The Guidelines–Atrial Fibrillation Program (2018) (3)
Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. (2022) (3)
Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study (2021) (3)
Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. (2022) (3)
Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. (2020) (3)
Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. (2015) (3)
Egg Consumption and Risk of Cardiovascular Disease: a Critical Review (2021) (3)
Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. (2016) (3)
Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event (2021) (3)
5257Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL (2018) (3)
Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs (2015) (2)
Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction (2015) (2)
The JCF Reviewer Mentorship Program. (2022) (2)
PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL (2019) (2)
The Characteristics and Outcomes of Advanced Heart Failure Patients with Hemodynamic Parameters Predictive of Right Ventricular Failure (2013) (2)
Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. (2018) (2)
Reaping from Reciprocity: the Mentor-Mentee Relationship. (2021) (2)
In-hospital outcomes after bariatric surgery in patients with heart failure. (2020) (2)
Sleep Breathing Disorders in Heart Failure. (2022) (2)
The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation. (2021) (2)
Smartphone 12-lead ECG-Exciting but must be handled with care. (2020) (2)
ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY (2017) (2)
OptiVol for Volume Assessment in Patients With Continuous Flow Left Ventricular Assist Device. (2020) (2)
Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. (2015) (2)
Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. (2021) (2)
Severity of functional impairments by race and sex in older patients hospitalized with acute decompensated heart failure (2022) (2)
Abstract 14733: Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality: The Lifetime Risk Pooling Project (2018) (2)
TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF (2017) (2)
Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group (2018) (2)
Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study (2018) (2)
Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together? (2020) (2)
RELIABLE EVALUATION OF DYSPNEA (RED-ROSE): A PROSPECTIVE ANCILLARY STUDY FROM THE RENAL OPTIMIZATION STRATEGIES EVALUATION IN ACUTE HEART FAILURE (ROSE-AHF) TRIAL (2014) (2)
Cardiovascular risk stratification in the noncardiac solid organ transplant candidate (2021) (2)
Sacubitril/valsartan Initiation and Adherence Patterns Following Hospitalization for Heart Failure (2020) (2)
Older Patients With Acute Decompensated Heart Failure Who Live Alone: An Analysis From the REHAB-HF Trial (2021) (2)
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. (2021) (2)
CHARACTERISTICS AND OUTCOMES OF HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS ENROLLED IN MEDICARE ADVANTAGE WITH AND WITHOUT RECENT WORSENING HEART FAILURE (2020) (2)
Abstract 196: Development and Validation of Machine Learning-based Race-specific Models to Predict 10-year Risk of Heart Failure: A Multi-cohort Analysis (2020) (2)
Evaluation and Treatment of Central Sleep Apnea in Patients with Heart Failure. (2022) (2)
Dysglycemia and Incident Heart Failure among Blacks: The Jackson Heart Study. (2021) (2)
Patterns of Change in Quality of Life with a Palliative Care Intervention for Patients with Advanced Heart Failure: Insights from PAL-HF (2019) (2)
Subcutaneous Furosemide in the Treatment of Patients with Decompensated Heart Failure: Data from the Sub-Q Pilot Studies (2019) (2)
Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply (2018) (2)
PROVIDE-HF STUDY RESULTS: PATIENT-REPORTED OUTCOMES INVESTIGATION FOLLOWING INITIATION OF DRUG THERAPY WITH ENTRESTO (SACUBITRIL/VALSARTAN) IN HEART FAILURE (2020) (2)
Do PRO measures function the same way for all individuals with heart failure? (2022) (2)
An evaluation of torsemide in patients with heart failure and renal disease (2021) (2)
Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. (2021) (2)
Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. (2022) (2)
Survival in Patients With Nonischemic Cardiomyopathy With Preserved vs Reduced Ejection Fraction (2021) (2)
Differences Between Patients with Cardiovascular Disease and Cancer Referred for Palliative Care. (2020) (2)
Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction (2021) (2)
Worsening Heart Failure Events in HFpEF: Underlying Biology Not Treatment Location. (2021) (1)
d-Dimer elevation and adverse outcomes The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2015) (1)
Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). (2021) (1)
Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction (2020) (1)
In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial (2022) (1)
Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance (2021) (1)
Hand grip strength predicts mortality and quality of life in heart failure: Insights from the Singapore Cohort of Patients with Advanced Heart Failure: Grip strength predicts mortality and quality of life in heart failure. (2022) (1)
Implications of Amiodarone Use Before Heart Transplantation (2016) (1)
Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does “X” Really Mark the Spot? (2019) (1)
Sudden Death Following Hospitalization for Heart Failure with Reduced Ejection Fraction (From the EVEREST Trial) (2018) (1)
Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. (2016) (1)
Heart Month - A Historical Look and Simple "Walk" of Acknowledgement in the Present. (2022) (1)
Traveling the Interstices of Data Sharing. (2018) (1)
A Roadmap to Reinvigorating Training Pathways Focused on the Care of Patients with Heart Failure: Shifting from Failure to Function. (2022) (1)
SOCIOECONOMIC STATUS, MARITAL STATUS AND OUTCOMES IN HEART FAILURE: FINDINGS FROM HF-ACTION (2014) (1)
Reply: Pragmatic Clinical Trials: The Big Picture. (2021) (1)
Physical Functioning in Heart Failure with Preserved Ejection Fraction: Physical Functioning in HFpEF. (2021) (1)
Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator? (2018) (1)
Return on Investment in Implantable Devices: Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure. (2017) (1)
Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019. (2022) (1)
Beta-blocker and ACE-inhibitor Dosing as a Function of Body Surface Area: From the HF-ACTION trial. (2020) (1)
Abstract 168: The ADHERE Risk Model for In-hospital Worsening Heart Failure (2015) (1)
Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). (2021) (1)
Intervention Adherence in REHAB‐HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events (2022) (1)
Patients Accept Mortality Risk for Improvements in Physical Functioning in Secondary Mitral Regurgitation (2019) (1)
A randomized controlled trial of mobile health intervention in patients with heart failure and diabetes. (2022) (1)
β blockers for heart failure: which works best? (2013) (1)
330 - Trends and Outcomes of Cardiac Transplantation From Donors Dying of Drug Intoxication (2017) (1)
PULMONARY HYPERTENSION IS ASSOCIATED WITH A HIGHER RISK OF HEART FAILURE AND MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE: THE JACKSON HEART STUDY (2017) (1)
INCREASED RISK OF SEVERE HYPOGLYCEMIC EVENTS BEFORE AND AFTER CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: VALIDATION OF A NOVEL CONCEPT (2019) (1)
Corrigendum to "Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America" Journal of Cardiac Failure Vol. 25 No. 8, pp. 584-619. (2019) (1)
Practical Patient Care Considerations with Use of Vericiguat After Worsening Heart Failure Events. (2022) (1)
Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. (2017) (1)
Is there a role for albumin and C-reactive protein levels for prognostication in acute heart failure? (2015) (1)
Abstract 17587: Implications of Angina Pectoris on Quality of Life, Functional Capacity and Clinical Outcomes in Chronic Heart Failure Patients: Insights From HF-ACTION (2015) (1)
Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. (2021) (1)
#WordsMatter Continued: Moving from "Candidacy" To "Benefit Derived". (2022) (1)
Abstract 17791: Predictors of Left Ventricular Thrombus Following ST-Segment Elevation Myocardial Infarction: Findings From the Duke Databank of Cardiovascular Disease and the Duke Echocardiography Databank (2013) (1)
Abstract 11623: Determination of the Diagnostic Accuracy of a Mobile Smartphone ECG Device Compared to a Standard 12-Lead ECG for Evaluation of ST-Segment Elevation Myocardial Infarction (STEMI). Primary Results of the ST LEUIS International Multicenter Study (2018) (1)
THE ASSOCIATION OF BETA-BLOCKER USE AND SELECTIVITY WITH OUTCOMES IN HEART FAILURE PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FINDINGS FROM THE ORGANIZED PROGRAM TO INITIATE LIFE-SAVING TREATMENT IN HOSPITALIZED PATIENTS WITH HEART FAILURE (2012) (1)
eGFR Variability in Patients with Heart Failure and Chronic Kidney Disease. (2021) (1)
Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease (2021) (1)
6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL (2019) (1)
Abstract 20769: Sudden Cardiac Death Risk After Hospitalization for Heart Failure: Insights From EVEREST (2017) (1)
Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) (2018) (1)
Respiratory Phase Detection From Seismocardiographic Signals Using Machine Learning (2022) (1)
Pragmatic Design of Randomized Clinical Trials for HeartFailure (1)
INFLUENCE OF BASELINE PHYSICAL ACTIVITY LEVEL ON CLINICAL OUTCOMES AND RESPONSES TO EXERCISE TRAINING IN PATIENTS WITH SYSTOLIC HEART FAILURE: INSIGHTS FROM HF-ACTION (2018) (1)
Phenomapping in heart failure with preserved ejection fraction - insights, limitations, and future directions. (2022) (1)
Siesmocardiographic Changes with HF Status Change: Observations from a Pilot Study (2018) (1)
Abstract P320: Temporal Trends In Prevalence & Prognostic Implications Of Cardiac And Non-cardiac Comorbidities Among Patients With Acute Decompensated Heart Failure: Aric Study Community Surveillance (2020) (1)
RESPONSE TO EXERCISE TRAINING AND OUTCOMES IN HEART FAILURE PATIENTS WITH DIABETES MELLITUS: INSIGHTS FROM HF-ACTION (2015) (1)
Patient-Centered Measures of Treatment Benefit. (2020) (1)
AEROBIC EXERCISE TRAINING AND HEALTH STATUS IN AMBULATORY HEART FAILURE PATIENTS WITH A REDUCED EJECTION FRACTION: AN ANALYSIS FROM THE HF-ACTION TRIAL (2016) (1)
The Universal Definition of Heart: Perspectives from Diverse Stakeholders. (2021) (1)
Proteomic differences among patients with heart failure taking furosemide or torsemide (2022) (1)
Sleep quality, depressive symptoms, and transplant outcomes: Follow-up analyses from the ADAPT prospective pilot study. (2021) (1)
Patients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study (2022) (1)
JCF Year-In-Review 2021 and the Path Forward. (2021) (1)
Ascertaining Death Events in a Pragmatic Clinical Trial: Insights from the TRANSFORM-HF Trial. (2022) (1)
Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction. (2012) (1)
Mechanisms of current therapeutic strategies for heart failure: more questions than answers? (2022) (1)
Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS‐HF trial (2019) (1)
The worst symptom visual analogue scale: a prospective ancillary study from the renal optimization strategies evaluation in acute heart failure (rose-AHF) trial (2014) (1)
Glycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study (2022) (1)
Abstract 342: Differences in Health Care Utilization and Outcomes Based on Timing of In-Hospital Worsening Heart Failure (2015) (1)
Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. (2022) (1)
Hand Grip Strength Predicts Mortality And Quality Of Life In Heart Failure: Insights From The Singapore Cohort Of Patients With Advanced Heart Failure (2023) (1)
Seismocardiography Feature Selection For Prediction Of Heart Failure Readmission (2022) (1)
PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL (2020) (1)
Beta-Blocker Selectivity in Heart Failure (HF) Patients With Chronic Obstructive Pulmonary Disease (COPD): Insights from HF-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) (2012) (1)
Abstract 9698: Cigarette Smoking and Incident Coronary Heart Disease in African Americans: The Jackson Heart Study (2019) (0)
Biomarkers in Advanced Heart Failure (2020) (0)
Randomization versus Real-World Evidence. (2020) (0)
958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis (2020) (0)
Abstract 109: In-Hospital Worsening Heart Failure is Associated With Poor Patient Outcomes and Increased Health Care Utilization (2014) (0)
PROGNOSTIC VALUE OF RIGHT-SIDED VOLUME OVERLOAD IN PATIENTS PRESENTING WITH ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF (2016) (0)
Advancing the #WordsMatter Movement: Changing Chief Complaint to Chief Concern. (2022) (0)
Computational and Mechanical Modeling of SCG Signals (2020) (0)
Abstract 13820: Temporal Trends and Prognosis of Physical Exam Findings in Patients Hospitalized With Acute Decompensated Heart Failure With Preserved versus Reduced Ejection Fraction the Aric Study Community Surveillance (2020) (0)
A Distinction Between Wellness and Resilience. (2023) (0)
Association between VE-VCO2 Slope and Resting Hemodynamic Measurements in Ambulatory Heart Failure (HF) Patients: An Analysis from the Duke Advanced HF Database (2011) (0)
Abstract 15973: The Association Between Blood Pressure Control and Outcomes Among Black Participants in the Jackson Heart Study (2015) (0)
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (2022) (0)
Constructive Criticism in Medicine: Heart Function Clinicians Leading Positive Change. (2023) (0)
Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF. (2022) (0)
Hospitalized Heart Failure in the United States Learned from Clinical Trial (2015) (0)
CLINICAL CHARACTERISTICS, RESPONSE TO EXERCISE AND OUTCOMES IN HEART FAILURE PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FINDINGS FROM HEART FAILURE – A CONTROLLED TRIAL INVESTIGATING OUTCOMES OF EXERCISE TRAINING (HF-ACTION) (2012) (0)
Response to Exercise Training and Outcomes in Patients with Heart Failure and Diabetes Mellitus: Insights from HF-ACTION (2016) (0)
Prognostic significance of polyvascular disease in patients admitted with acute decompensated heart failure: the ARIC Study Community Surveillance (2021) (0)
RESTING HEART RATE AND LONG-TERM OUTCOMES IN AFRICAN AMERICANS: INSIGHTS FROM THE JACKSON HEART STUDY (2016) (0)
JCF Heart Failure Year-In-Review 2022… The Best is Yet to Come! (2023) (0)
Review Article Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact (2015) (0)
Dependence Of SCG Clustering On SCG Measurement Location (2022) (0)
Physical Rehabilitation in Patients with Heart Failure. Reply. (2021) (0)
Non-participation in a Heart Failure Clinical Trial: Perspectives and Opportunities from the VICTORIA Trial and Simultaneous Registry (2020) (0)
DIFFERENCES IN THERAPY AND DECONGESTION BETWEEN MEN AND WOMEN HOSPITALIZED FOR ACUTE HEART FAILURE: FINDINGS FROM ASCEND-HF (2020) (0)
Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database. (2022) (0)
TEMPORAL TRENDS IN NON-CARDIOVASCULAR COMORBIDITIES AMONG PATIENTS HOSPITALIZED WITH ACUTE VS CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE ARIC STUDY (2021) (0)
Investigating Potential Gender-Based Differential Item Functioning for Items in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Physical Limitations Domain (2023) (0)
Abstract 15883: Home-Time as a Novel Post-Discharge Outcome for Patients Hospitalized With Heart Failure (2017) (0)
Abstract 933: Integrated Omics Analysis of Diabetic Heart Failure in Human Myocardium (2019) (0)
Torsemide vs. Furosemide in Heart Failure Patients: Insights from Duke University Hospital (2014) (0)
SUBCLINICAL ATHEROSCLEROSIS, STATIN ELIGIBILITY, AND OUTCOMES IN AFRICAN AMERICANS: THE JACKSON HEART STUDY (2017) (0)
The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure (2016) (0)
Loop Diuretic Dose Adjustments After a Hospitalization for Heart Failure: Insights from ASCEND-HF (2014) (0)
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure (2022) (0)
P6030Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry (2018) (0)
PCV7 DO MEN AND WOMEN INTERPRET THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE (KCCQ) DIFFERENTLY? (2020) (0)
Abstract 13559: Gender Does Not Impact Post-Discharge Outcomes in Patients Hospitalized for Worsening Heart Failure with Reduced Ejection Fraction in the EVEREST Trial (2011) (0)
EFFECTS OF AGE AND COMORBIDITIES ON OUTCOMES IN PATIENTS WITH HEART FAILURE FROM HF-ACTION (2017) (0)
Previous Hospitalizations Predict Worse Outcomes after Discharge Despite Achievement of Diuresis during ADHF Hospitalization (2013) (0)
Abstract 10990: Regulatory Implications of Different Definitions and Outcomes in Worsening Heart Failure (2015) (0)
ASSOCIATIONS OF DIABETES AND HYPERTENSION WITH LEFT VENTRICULAR MASS-THE JACKSON HEART STUDY (2020) (0)
Intravenous iron infusion in patients with heart failure: a systematic review and study‐level meta‐analysis (2023) (0)
Patients with a Mid-Range Ejection Fraction (2017) (0)
Increased eGFR Variability is Observed in Patients with HFrEF Compared to no HF or HFpEF in the Setting of Chronic Kidney Disease (2019) (0)
Overcoming Inertia: Announcing Double Blinded Reviews at JCF. (2021) (0)
PART D OUT OF POCKET PAYMENTS IN MEDICARE BENEFICIARIES WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (2021) (0)
Table of Contents (2020) (0)
Abstract 20336: A Novel Risk Score That Includes Lipoprotein Sub-Particles Enhances the Prediction of Severe Coronary Artery Disease and Adverse Cardiovascular Outcomes: Validation From Jackson Heart Study (2017) (0)
Torsemide Is Associated with Higher Levels of Urinary Biomarkers of Tubular Injury Compared to Furosemide (2020) (0)
1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial (2020) (0)
PROGNOSTIC ROLE OF HEMOCONCENTRATION IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS OF THE EVEREST TRIAL (2013) (0)
β blockers for heart failure: which works best? There seems to be a class effect; "some blocker is better than no blocker" (2013) (0)
Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL (2018) (0)
Abstract 11923: Perceived Discrimination and Cardiovascular Outcomes in Older African Americans: Insights From the Jackson Heart Study (2016) (0)
Abstract 18883: High Sensitivity Troponin T in Acute Heart Failure: Insights from RELAX-AHF (2014) (0)
Documenting Spatial Variation of SCG Signals for Optimal Sensor Placement (2020) (0)
Abstract 14727: Meteorin-like Glial Cell Differentiation Regulator is a Novel Protein Biomarker of Cardiovascular Outcomes in Patients With Diabetes and Vascular Disease: A TECOS Substudy (2020) (0)
Early Identification of Patients At-Risk for Incident Heart Failure with Preserved Ejection Fraction (HFpEF): Novel Approach to Echocardiographic Trends. (2021) (0)
Abstract 16682: Regional Differences in Heart Failure Medication Changes During Acute Heart Failure Hospitalization: Findings From the PROTECT Trial (2013) (0)
Abstract 16058: Country Income Level, Protocol Completion, and Trial Endpoints Among Patients With Acute Heart Failure: Insights From the ASCEND-HF Trial (2017) (0)
DECONGESTION STRATEGIES AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ACTIVATION IN ACUTE HEART FAILURE (2014) (0)
Abstract 17580: Angina Pectoris in Diabetic Patients: Insights From the Duke Databank for Cardiovascular Disease (2015) (0)
Heart Failure Care in the United States (2015) (0)
ASSOCIATION BETWEEN ASSIGNMENT TO AN ACCOUNTABLE CARE ORGANIZATION AND QUALITY OF CARE AND OUTCOMES AMONG MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2019) (0)
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials. (2023) (0)
Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure. (2017) (0)
Abstract 10738: Comparative Outcomes of Sacubitril/Valsartan Use Among Medicare Beneficiaries NaïVe to Renin-angiotensin System Inhibitors and Hospitalized with Heart Failure (2021) (0)
Abstract 13456: Characterizing Changes in Quality of Life and in Older Patients With Acute Decompensated Heart Failure Enrolled in a Rehab Intervention Clinical Trial (2021) (0)
PRIOR HEART FAILURE HOSPITALIZATION AMONG PATIENTS HOSPITALIZED FOR WORSENING CHRONIC HEART FAILURE: FROM THE ASCEND-HF TRIAL (2018) (0)
She Was One of Us. Remembering Dr. Lauren Gilstrap (2022) (0)
Author response for "Effect of once‐weekly exenatide on eGFR slope depends on baseline renal risk: a post‐hoc analysis of the EXSCEL trial" (2020) (0)
Causes of Death Among Patients with and without DIabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry (2018) (0)
Abstract 14697: Ventricular Conduction and Long-term Outcomes in African Americans: Insights from the Jackson Heart Study (2014) (0)
Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry (2022) (0)
Abstract 13641: Serum Vitamin D3 Levels, Left Ventricular Structure and Incident Hospitalization for Heart Failure With Preserved Ejection Fraction in African Americans: The Jackson Heart Study (2020) (0)
Advancing Our Common Purpose Through "Coopetition". (2022) (0)
Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications (2021) (0)
Reply (2021) (0)
A Global Perspective/Health Inequity in Heart Failure. (2015) (0)
Abstract 13158: Hospitalization for De Novo versus Worsening Chronic Heart Failure: Insights From the ASCEND-HF Trial (2016) (0)
Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. (2023) (0)
Fostering Belonging at JCF. (2022) (0)
STATINS AND EXERCISE TRAINING RESPONSE IN HEART FAILURE PATIENTS: INSIGHTS FROM THE HF-ACTION TRIAL (2015) (0)
Comparable Clinical Benefits with Beta-Blockers in Heart Failure Patients from North America and Europe: Evidence from a Meta-Analysis of Randomized Clinical Trials (2013) (0)
EMERGENCY DEPARTMENT VISITS VERSUS HOSPITAL READMISSION AMONG PATIENTS WITH HEART FAILURE: FINDINGS FROM ASCEND-HF (2021) (0)
#ConstructivelyDisruptive - Breaking Molds at JCF. (2022) (0)
Impact of Diabetes and Hypertension on Left Ventricular Structure and Function: The Jackson Heart Study. (2023) (0)
Following Our Hearts: Prioritizing Self-care and Wellness. (2021) (0)
Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America. (2023) (0)
Clinical Characteristics and Outcomes of Patients with Ischemic Cardiomyopathy (ICM) and Angina: Findings from the Duke Cardiovascular Database (2011) (0)
Participating in the Peer Review Process: The Journal of Cardiac Failure Construct. (2022) (0)
EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus (2018) (0)
The Use of the Multisensor HeartLogic Algorithm for Heart Failure Remote Monitoring in Patients With Left Ventricular Assist Devices. (2023) (0)
Nitrate Use And Changes In Functional Status In Black Patients With Chronic Heart Failure With Reduced Ejection Fraction: Insights From The HF-ACTION Trial (2020) (0)
Abstract 16738: International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS (2017) (0)
EARLY IMPACT OF GUIDELINE PUBLICATION ON ANGIOTENSIN-RECEPTOR NEPRILYSIN INHIBITOR USE AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE (2018) (0)
Remembering the Calling - Where Patients and Caregivers Are Front and Center. (2021) (0)
Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF (2016) (0)
In-Hospital Outcomes in Pregnancy After Heart Transplantation. (2022) (0)
Volume Assessment and Management: Medical and Device Therapies (2016) (0)
THE RELATIONSHIP BETWEEN BIOMARKERS OF INFLAMMATION AND LEFT VENTRICULAR STRUCTURE AND FUNCTION (2021) (0)
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events (2022) (0)
Worsening Heart Failure During Hospitalization for Acute Heart Failure: Insights from ASCEND-HF (2015) (0)
Potassium Abnormalities Across the Spectrum of Heart Failure. (2019) (0)
The Palliative Care in Heart Failure (PAL-HF) Trial: Rationale and Design (2014) (0)
Abstract 13253: Race, Exercise Training and Outcomes in Chronic Heart Failure (2012) (0)
Abstract 14931: Early Repolarization Defined as J-Point Elevation and Mortality in African Americans: Insights From the Jackson Heart Study (2016) (0)
Clinical Investigation The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study (2016) (0)
Abstract 11230: Timing of Readmission Following Heart Failure Hospitalization - Before and After 30 Days (2014) (0)
Abstract 15589: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in People With Type 2 Diabetes Mellitus and Vascular Disease: A Tecos Substudy (2020) (0)
Vericiguat for the treatment of heart failure with reduced ejection fraction (2023) (0)
Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF (2015) (0)
High Intensity Interval Training Versus Moderate Continuous Training in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. (2023) (0)
173 - Loop Diuretic Change in Patients with Chronic Heart Failure: Insights From HF-ACTION (2017) (0)
TCT-404 Acute Heart Failure Hospitalizations Following Transcatheter Aortic Valve Replacement in the United States (2021) (0)
Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction. (2017) (0)
Abstract 257: Discharge Heart Rate and Beta-blocker Dose in Patients Hospitalized with Acute Heart Failure (2015) (0)
Abstract 13302: Worsening Heart Failure During Acute Heart Failure Hospitalization: Insights from ASCEND-HF (2014) (0)
Translating Nursing Partnerships in Clinical Care to Scientific Publishing. (2022) (0)
Continuous Monitoring of Heart Rate Variability and Clinical Outcomes in Patients with Implantable Cardioverter Defibrillators. (2022) (0)
Patients With Type 2 Diabetes Are More Resistant To Diuresis And Have Worse Acute Heart Failure Outcomes: Findings From ASCEND-HF (2023) (0)
Abstract 16818: Circulating Cardiac Troponin I as Detected By a High-Sensitivity Assay among Patients Hospitalized with Acute Decompensated Heart Failure (2011) (0)
Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. (2023) (0)
Insufficient Reduction in Heart Rate during Hospitalization Despite Beta-Blocker Treatment in Acute Decompensated Heart Failure (2016) (0)
Home-Time as a Novel Post-Discharge Outcome for Patients Hospitalized with Heart Failure (2019) (0)
Abstract 023: Left Ventricular Hypertrophy and Elevated Biomarkers of Chronic Myocardial Injury May Identify African Americans With a Very High Risk for Heart Failure Development: Findings From The Jackson Heart Study (2018) (0)
Abstract 14450: Association of Trajectory of High Sensitivity C-reactive Protein and Incident Heart Failure in African Americans: The Jackson Heart Study (2020) (0)
Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure (2021) (0)
Erratum to ‘The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963–972] (2019) (0)
HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF (2017) (0)
Abstract 16697: Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From the American Heart Association’s Get With the Guidelines-Heart Failure Registry (2016) (0)
301 - The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF (2017) (0)
Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). (2020) (0)
Clinical Trajectory of Patients with a Worsening Heart Failure Event and Reduced Ventricular Ejection Fraction. (2021) (0)
Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. (2022) (0)
Adoption of Sacubitril/Valsartan Among Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The Get With the Guidelines - Heart Failure Registry. (2022) (0)
Using Death as an Endpoint (2017) (0)
INFLUENCE OF URIC ACID LEVEL IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
International Collaborations in Heart Failure: JCF in Latin America. (2022) (0)
THE RELATIONSHIP BETWEEN BODY WEIGHT CHANGE DURING HOSPITALIZATION FOR ACUTE HEART FAILURE AND PATIENT CHARACTERISTICS, MARKERS OF CONGESTION, AND OUTCOMES: FINDINGS FROM ASCEND-HF (2016) (0)
A Case for Re-Gifting (2021) (0)
Induction Therapy after Heart Transplantation. (2020) (0)
Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment: Insights From the HF-ACTION Trial (2018) (0)
Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire with a Palliative Care Intervention for Patients with Advanced Heart Failure: Insights from PAL-HF. (2021) (0)
Abstract 15401: Hypertensive Diseases in Pregnancy and Renal Function Later in Life: Insights From the Genetic Epidemiology Network of Arteriopathy Study (2019) (0)
The PROTECT In-Hospital Risk Model: 7-Day Outcome in Patients Hospitalized with Acute Heart Failure (AHF) and Renal Dysfunction (2011) (0)
Abstract 16647: Clinical Characteristics and Outcomes of Patients With Ischemic Cardiomyopathy and Persistent Angina Pectoris: From the Duke Databank for Cardiovascular Disease (2013) (0)
INFLUENCE OF CLINICAL TRIAL SITE ENROLLMENT ON PATIENT CHARACTERISTICS, PROTOCOL COMPLETION, AND ENDPOINTS: INSIGHTS FROM THE ASCEND-HF TRIAL (2016) (0)
The PROTECT In-Hospital Risk Model (2011) (0)
ASSOCIATION BETWEEN ANGINA AND OUTCOMES IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION: ANALYSIS FROM THE DUKE DATABANK FOR CARDIOVASCULAR DISEASE (2013) (0)
Abstract 14837: Social Determinants of Health and Outcomes in Patients With Advanced Heart Failure: Findings From PAL-HF (2020) (0)
Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials: Inconsistent Outcome Reporting in HF RCTs. (2022) (0)
Quality of Life Trajectory and Its Mediators in Older Patients With Acute Decompensated Heart Failure Receiving a Multi-Domain Rehabilitation Intervention: Results From the Rehabilitation Therapy in Older Acute Heart Failure Patients Trial (2022) (0)
Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials (2021) (0)
Abstract 15532: Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and a Worsening Heart Failure Event (2020) (0)
Catastrophic Disruptions in Clinical Trials. (2022) (0)
WHO? CHARACTERIZING VERICIGUAT USE IN A REAL-WORLD HFREF PATIENT POPULATION (2023) (0)
Recognizing Efforts that Support Clinical Trial Success: Site-Based Research Awards from the Heart Failure Collaboratory and Heart Failure Society of America. (2022) (0)
Clinical Characteristics and Outcomes for Hospitalized Heart Failure (HF) Patients with Chronic Obstructive Pulmonary Disease (COPD): Findings from OPTIMIZE-HF (2011) (0)
RACE AND SEX DIFFERENCES IN THE QRS INTERVAL AMONG PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (2015) (0)
Abstract 14073: Trajectory of Congestion Metrics by Ejection Fraction in Acute Heart Failure - Findings From the Heart Failure Network (2016) (0)
Assessing for a Differential Treatment Effect with Nesiritide by Body Mass Index (2020) (0)
Abstract 13328: Coronary Artery Disease is Associated with a Poor Post-Discharge Prognosis in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: Findings from the EVEREST Trial (2011) (0)
Shining a light on the vulnerable intersection of pregnancy and heart failure. (2021) (0)
Abstract 14658: Comparative Effectiveness of Torsemide versus Furosemide in Acute Heart Failure Patients: Insights from ASCEND-HF (2014) (0)
SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
A Gordian knot: disentangling comorbidities in heart failure (2016) (0)
Abstract 11459: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in Individuals with Type 2 Diabetes Mellitus: An Exscel Biomarker Substudy (2021) (0)
CHARACTERISTICS AND OUTCOMES OF TRIAL-ELIGIBLE VS INELIGIBLE PATIENTS WITH HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION (2023) (0)
IMPACT OF SEVERE DYSPNEA ON OUTCOMES AND HEALTH CARE COSTS IN PATIENTS HOSPITALIZED WITH HEART FAILURE (2014) (0)
Physical Activity and Relationship to Physical Function, Quality of Life, and Cognitive Function in Older Patients with Acute Decompensated Heart Failure. (2022) (0)
Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction. (2022) (0)
PCV136 PATIENT PREFERENCES FOR MITRAL VALVE PROCEDURE-ASSOCIATED BENEFITS REVEAL GREATER RISK TOLERANCE AS HEART FAILURE SYMPTOMS WORSEN (2019) (0)
Abstract 15393: Physical Activity, Chronic Myocardial Injury and Risk of Heart Failure in African Americans: The Jackson Heart Study (2018) (0)
TIME OF PRESENTATION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE (CLINICAL CHARACTERISTICS, INITIAL THERAPIES AND OUTCOMES): INSIGHTS FROM ASCEND-HF (2017) (0)
PROTEOMIC MARKERS OF CARDIAC FIBROSIS AND ENDOTHELIAL FUNCTION ASSOCIATED WITH HEART FAILURE IN PATIENTS WITH DIABETES: AN EXSCEL BIOMARKER SUB-STUDY (2023) (0)
The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. (2021) (0)
Percutaneous Coronary Interventions in Patients Supported with Left Ventricular Assist Devices (2021) (0)
Low-risk pragmatic trials with medicines and the need for participant’s informed consent (2018) (0)
Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF (2015) (0)
RATIONALE AND DESIGN FOR A PHASE 2 TRIAL OF VERINURAD PLUS ALLOPURINOL IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND HYPERURICEMIA (2021) (0)
P1814Deaths and vascular outcomes with non-vitamin K oral anticoagulants versus warfarin in patients with heart failure in the food and drug administration adverse event reporting system (2018) (0)
DECONGESTION, QUALITY OF LIFE, AND CLINICAL OUTCOMES AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED VERSUS PRESERVED EJECTION FRACTION (2022) (0)
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (2023) (0)
Abstract 20846: The Impact of a Palliative Care Intervention on Polypharmacy in Advanced HF: Results From Pal-HF (2017) (0)
Corrigendum to "Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example" [Contemporary Clinical Trials volume 88 (2020) 105775]. (2021) (0)
Response to "Global cardiovascular clinical trials and geographic altitude". (2013) (0)
Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: Results From the DYSPNEA‐AHF Study: 67EMF (2018) (0)
ASSOCIATION BETWEEN BLOOD TYPE AND OUTCOMES OF BRIDGE-TO-TRANSPLANT LEFT VENTRICULAR ASSIST DEVICE THERAPY: ANALYSIS OF THE UNITED NETWORK FOR ORGAN SHARING (UNOS) REGISTRY (2022) (0)
Abstract 21023: Population Attributable Risk for Cardiovascular Disease Associated With Hypertension and Prehypertension in African Americans: The Jackson Heart Study (2017) (0)
Abstract 13323: Chronic Obstructive Pulmonary Disease is Associated with Adverse Events in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: An Analysis of the EVEREST Trial (2011) (0)
PREVALENT DIGOXIN USE IS NOT ASSOCIATED WITH INCREASED RISK OF DEATH OR HOSPITALIZATION IN AMBULATORY HEART FAILURE PATIENTS WITH A REDUCED EJECTION FRACTION (2017) (0)
Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction (2022) (0)
International Differences in Acute Heart Failure (AHF) Patients : Insight from the PROTECT Trial (2011) (0)
Vitamin D Levels in Black Americans and the Association with Left Ventricular Remodeling and. (2022) (0)
P4904Multi-ethnic comparisons of diabetes in heart failure with reduced ejection (2017) (0)
Abstract P160: Relationship of Physical Function and Quality of Life in Elderly Patients With Acute Decompensated Heart Failure: The Rehabilitation Therapy in Older Acute Heart Failure Patients (The REHAB-HF Trial) (2018) (0)
Association of body surface area with target dose guideline-directed therapy in an international cohort of patients with heart failure (2018) (0)
Unsupervised Machine Learning To Define Acute Hfpef Phenotypes: Findings From Ascend-hf (2022) (0)
Nondilated Left Ventricle as an Adding Clue Helping Discrimination Between Acute Myocarditis From Other Cardiomyopathies (2016) (0)
Trajectory of high sensitivity c-reactive protein and incident heart failure in black adults: the jackson heart study (2023) (0)
Rehabilitation Therapy In Older Patients Hospitalized With Acute Heart Failure And Comorbid Diabetes: Insights From Rehab-hf (2022) (0)
ELECTROCARDIOGRAPHIC T WAVE INVERSION IS ASSOCIATED WITH INCIDENT HEART FAILURE IN BLACK AMERICANS: THE JACKSON HEART STUDY (2023) (0)
Longitudinal changes in cardiac troponin and risk of heart failure among Black adults. (2022) (0)
Wednesday, 29 August 2012 (2012) (0)
MINERALOCORTICOID RECEPTOR ANTAGONISTS IN DIABETIC PATIENTS HOSPITALIZED WITH HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
Advancing the Evidence for Diuretic Therapy for Heart Failure: Implications of the ADVOR and TRANSFORM-HF Trials. (2023) (0)
Novel Therapeutic Concepts Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction : integrating evidence into clinical practice (2012) (0)
608 Impact of obesity on cardiovascular prognosis: new data IMPACT OF OBESITY ON CARDIOVASCULAR PROGNOSIS: NEW DATA (0)
Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. (2020) (0)
Abstract P319: Racial Differences and Temporal Trends in Obesity Among Patients Hospitalized With Acute Decompensated Heart Failure With Preserved Ejection Fraction: The ARIC Study Community Surveillance (2020) (0)
Cardiorenal Clinical Trial End Points (2011) (0)
IMPACT OF DONOR BRAIN DEATH DURATION ON OUTCOMES FOLLOWING HEART TRANSPLANTATION: A UNOS REGISTRY ANALYSIS (2020) (0)
FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL (2022) (0)
Lifting and Healing as We Climb: Women's Heart Month. (2023) (0)
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/valsartan versus Valsartan in HFmrEF and HFpEF with a Worsening Heart Failure Event. (2023) (0)
MODE OF DEATH FOR MEN AND WOMEN WITH ACUTE HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION: FROM THE ASCEND-HF TRIAL (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert John Mentz?

Robert John Mentz is affiliated with the following schools:

University of Louisville
Duke University

Robert John Mentz's Academic­Influence.com Rankings